Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Bioventus ( (BVS) ) has shared an update.
On November 14, 2025, Bioventus Inc. appointed Ajay Dhankhar, PhD, as a Class II director, effective immediately, with his term ending at the 2026 annual stockholders meeting. Dr. Dhankhar, who has extensive experience in corporate development and strategy within the healthcare sector, is the second designee of the S+N Stockholders to the Board, alongside Philip G. Cowdy. His appointment aligns with the Stockholders Agreement, which allows Smith & Nephew affiliates to designate directors based on their shareholding. Dr. Dhankhar will not receive compensation from the company for his role.
The most recent analyst rating on (BVS) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Bioventus stock, see the BVS Stock Forecast page.
Spark’s Take on BVS Stock
According to Spark, TipRanks’ AI Analyst, BVS is a Neutral.
Bioventus’s overall stock score is driven by strong earnings call performance and solid financial improvements, particularly in cash flow and debt reduction. However, valuation concerns due to a negative P/E ratio and lack of dividend yield, along with mixed technical indicators, temper the overall score.
To see Spark’s full report on BVS stock, click here.
More about Bioventus
Average Trading Volume: 337,259
Technical Sentiment Signal: Sell
Current Market Cap: $608.3M
For detailed information about BVS stock, go to TipRanks’ Stock Analysis page.